A phase II trial of the sphingosine 1-phosphate 1 receptor modulator amiselimod has indicated that the drug is effective and safe in patients with relapsing–remitting multiple sclerosis. 415 patients were randomly assigned to receive 0.1 mg, 0.2 mg or 0.4 mg amiselimod or a placebo. The median total number of gadolinium-enhanced T1-weighted lesions during a 24-week treatment period was lower among patients who received 0.2 mg or 0.4 mg amiselimod than among those who received 0.1 mg or placebo. No serious adverse events were reported.
References
Kappos, L. et al. Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. http://dx.doi.org/10.1016/S1474-4422(16)30192-2 (2016)
Rights and permissions
About this article
Cite this article
Fyfe, I. Successful trial of amiselimod for multiple sclerosis. Nat Rev Neurol 12, 554 (2016). https://doi.org/10.1038/nrneurol.2016.128
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2016.128